Attracting sufficient equity capital to fund critical research is often a challenging task for the industry. This problem is exacerbated by an outdated tax regime that was largely set in place well before the advent of the modern biotechnology industry. The federal government should lead the effort in providing favorable tax and regulatory environments that will create incentives for economic development and job creation in the life sciences sector similar to the ongoing efforts at the state level.